People Want an Alzheimer’s Drug. Aducanumab Isn’t the One.

An F.D.A. sign-off for aducanumab would make finding a good treatment harder.

from NYT > Top Stories https://ift.tt/34psXgz Read about Implantation bleeding quiz https://urlzs.com/fZw6K Chlamydia in men https://urlzs.com/W3NV1 https://ift.tt/2KrY6cn https://youtu.be/QFwQ6JvyPa8